Deploys Capital into Cash-Flowing Manufacturing Businesses in Aerospace, Defense and IT Packaging -- Advances Dual Myostatin Assets Targeting Muscle Preservation in Potential Combination with GLP-1 ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA ...

Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc.

Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in ...

Q4 2025 Earnings Call March 25, 2026 5:00 PM EDTCompany ParticipantsLori Babcock - Chief of StaffTim Johnson - Founder, CEO ...

WASHINGTON, DC / ACCESS Newswire / March 24, 2026 / A new federal initiative allowing up to $500 annually in hemp-derived cannabinoid products for Medicare beneficiaries is raising urgent questions ...

Thank you, operator. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford. Earlier today, Rani released financial ...

Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion ...

Intrusion Shield expansion efforts and strategic enhancements to the sales process strengthen the Company's path toward ...

The acquisition is expected to further strengthen Rocket Lab’s proven capabilities as a leading launch provider, spacecraft manufacturer, and supplier of satellite components at scale to the global ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults furt ...